Difference between revisions of "Sirolimus (Rapamune)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Autoimmune cytopenia medications" to "Category:Autoimmune cytopenias medications") |
m |
||
| Line 4: | Line 4: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Autoimmune cytopenias]] | *[[Autoimmune cytopenias]] | ||
| − | *[[ | + | *[[Erdheim-Chester disease]] |
*[[Hodgkin lymphoma]] | *[[Hodgkin lymphoma]] | ||
==Also known as== | ==Also known as== | ||
| − | AY 22989 | + | *'''Code names:''' AY 22989, SILA 9268A, SLM, WY-090217 |
| + | *'''Generic names:''' RAPA, rapamycin | ||
| + | *'''Brand name:''' Rapamune | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | |||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| Line 18: | Line 19: | ||
[[Category:Autoimmune cytopenias medications]] | [[Category:Autoimmune cytopenias medications]] | ||
| − | [[Category: | + | [[Category:Erdheim-Chester disease medications]] |
[[Category:Hodgkin lymphoma medications]] | [[Category:Hodgkin lymphoma medications]] | ||
[[Category:Drugs FDA approved in 1999]] | [[Category:Drugs FDA approved in 1999]] | ||
Revision as of 19:34, 6 November 2017
Mechanism of action
From the NCI Drug Dictionary: A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian target of rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production.
Diseases for which it is used
Also known as
- Code names: AY 22989, SILA 9268A, SLM, WY-090217
- Generic names: RAPA, rapamycin
- Brand name: Rapamune